Vandervoort Adam C 4

What Happened
Adam C. Vandervoort, Teladoc Health’s Chief Legal Officer and Secretary, reported conversions/vestings of performance and restricted stock units and an open‑market sale. The filing shows he converted/received a number of PSUs/RSUs (totaling tens of thousands of underlying shares from multiple awards) and on March 2, 2026 sold 27,083 shares in the open market at $5.12 per share for proceeds of $138,584. Several converted shares were surrendered with $0 proceeds to satisfy tax withholding obligations.

Key Details

• Transaction dates: primary activity on Feb 27, 2026 (multiple conversions/vestings) and Mar 1–2, 2026 (additional grant on Mar 1; sale on Mar 2). Filing date: Mar 3, 2026 (appears timely).
• Open-market sale: 27,083 shares sold on 2026-03-02 at $5.12, proceeds $138,584.
• Conversions/exercises (listed as “M” derivative exercises) on 2026-02-27 total 49,590 shares converted (4,418 + 5,350 + 36,610 + 1,510 + 1,702). Matching $0.00 disposition entries indicate shares were surrendered to cover tax withholding.
• Awards/grants: reported acquisitions include 5,107 shares on 2026-02-27 and 181,661 shares on 2026-03-01 (reported as awards/earned performance stock units).
• Footnotes: PSUs and RSUs convert one‑for‑one into common stock (F1,F2,F8,F12). One‑third of certain awards vested on Mar 1, 2026, with remaining amounts vesting in eight substantially equal quarterly installments (F10, F11, F13). F3 notes shares were sold to cover tax withholding. F9 indicates performance awards reflect 2025 financial results.
• Shares owned after the transactions: not specified in the data provided.

Context

• These filings mainly reflect vesting/conversion of restricted and performance awards and routine tax-withholding sales, not an outright open-market buy. The March 2 open‑market sale produced modest proceeds (~$138.6k).
• The zero‑proceeds dispositions tied to the derivative entries indicate a cashless settlement or shares withheld/surrendered to satisfy tax withholding rather than a market sale.
• Filing date (Mar 3, 2026) appears to be within the required reporting window for the listed transaction dates.